Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients.

ABSTRACT:

Background

Lymphopenia is a hallmark of severe coronavirus disease 19 (COVID-19). Similar alterations have been described in bacterial sepsis and therapeutic strategies targeting T cell function such as recombinant human interleukin 7 (rhIL-7) have been proposed in this clinical context. As COVID-19 is a viral sepsis, the objectives of this study were to characterize T lymphocyte response over time in severe COVID-19 patients and to assess the effect of ex vivo administration of rhIL-7.

Results

Peripheral blood mononuclear cells from COVID-19 patients hospitalized in intensive care unit (ICU) were collected at admission and after 20 days. Transcriptomic profile was evaluated through NanoString technology. Inhibitory immune checkpoints expressions were determined by flow cyto

SUBMITTER: Bidar F 

PROVIDER: S-EPMC8896969 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature